The VYNE Therapeutics KOL Webinar will feature a presentation from Gerald V. Denis, PhD (Boston University School of Medicine) and Thierry Passeron, MD, PhD (University Hospital of Nice). Dr. Denis will provide a background on pan-bromodomain and extra-terminal (“BET”) inhibition for the treatment of various immuno-inflammatory conditions, and Dr. Passeron will then discuss the current treatment landscape and unmet medical need in treating patients with vitiligo.

The VYNE leadership team will provide a company update, as well as present preclinical data for their lead BET inhibitor, VYN201.

A live question and answer session will follow.